Unicycive Therapeutics Faces Class-Action Over FDA CRL Tied to Vendor Manufacturing
A securities class action accuses Unicycive of misstatements related to an FDA Complete Response Letter for OLC, citing third-party manufacturing deficiencies. The June 30, 2026 disclosure caused a 39% intraday drop, highlighting regulatory and manufacturing risk. The suit could pressure the stock and extend litigation-related uncertainty into 2027.
View signal analysis